Agibot is doing what a company does when the queue stops moving. From 22 October it began publishing seven results across seven consecutive working days, covering datasets, an operations platform, the heavy-load G2 Max, an embodied agent framework called GenieMaster, a simulation platform, a foundation model and a swarm learning method.
The backdrop is a 180-degree turn in how capital markets treat embodied AI between the start of this year and the end of it. Everyone in the sector rushed toward public markets. Most of the IPOs have since become uncertain events.
For Agibot specifically, reports say the company recently opened a new round at a valuation of roughly RMB 50 billion, while the IPO has been put on hold.
The detail that matters is in the secondary market. Unitree listed on the STAR Market in August, touched a market value above RMB 440 billion intraday, and lost almost half of it within days, with more than RMB 200 billion erased. In Hong Kong, the component maker Mech-Mind drew about 3,835 times oversubscription, a record for a robot name, and broke on its first day. The stock has kept drifting.
Pausing is not abandoning
A pause looks like a judgement call. At the point where the sector’s valuation froth is clearing, going on stage to be examined under a magnifying glass is worse than going back inside to work on the business. The standard by which the market judges has switched from prototypes, concepts and stories to order quality, customer repeat purchases and how real the commercial numbers are.
One more machine sold is worth more than one more point of share price.
The rulebook explains part of the delay. Under Chapter 18C for specialist technology companies, a company that files and then completes a new funding round before listing must wait 120 days after the round closes before it can proceed, unless the exchange grants a waiver. A new round objectively pushes the timetable out for everyone still queuing.
The environment did the rest. The Hong Kong exchange has signalled a consultation in the first half of next year on the 18C regime, including a review of the market value threshold, which will affect dozens of queuing embodied AI companies. On the mainland, the STAR Market revised its listing rules in June, naming robots and embodied intelligence as priority sectors while tightening admission and financial verification.
More than 50 embodied AI companies are queuing in Hong Kong, according to Wind. The queue has already split. Upstream component makers have had a smoother path, with Rokae, Seer, Mech-Mind and Benmo all completing Hong Kong listings. Full-airframe humanoid companies face stronger resistance, and a bell-ringing ceremony for one of them looks unlikely in the near term.
Two names, seventy per cent
Agibot and Unitree form a duopoly. SAG counts 8,400 Agibot units and 5,900 Unitree units in the first half of 2026, together more than 70 per cent of global share. No other single vendor broke a thousand units. Unitree has been profitable before.
The sector’s shared problem is the shape of demand. The Humanoid Robot Application Alliance counted 218 public tender wins in China in the first half, worth RMB 1.723 billion. Education and research institutions took 55.5 per cent, government and state platforms 20.6 per cent, and industrial enterprises 21.1 per cent. Inside that industrial share, most of it is prototype testing, showroom display and training pilots rather than routine production purchasing.
Research budgets move with project cycles, which makes repeat purchasing hard and revenue lumpy. That is the risk regulators and public market investors keep returning to, and it applies to almost every airframe maker.
Agibot has some evidence on the other side. Six G2 units are due to run a 24-hour livestreamed shift in a working convenience store on 2 and 3 November, a full-stack test in a real environment. At the company’s 2026 partner conference, founder and chief executive Deng Taihua set out the revenue path: RMB 300,000 in the first year, more than RMB 60 million in the second, past RMB 1 billion in 2025, roughly twenty-fold growth a year, several-fold growth again this year and RMB 10 billion targeted for 2027.
None of that means the product is finished. Reported shipments include wheeled and half-size platforms, and full-size deployment still has room to grow. Most Chinese airframe makers buy reducers, servo motors and controllers from the same small group of suppliers, so prototypes that walk and perform are easy and differentiation sits in appearance and choreography. Working in unstructured industrial settings needs far more condition data.
The second curve is abroad
Deng has said the company is not chasing net profit yet and will keep research spending saturated. That carries a cash cost, and Agibot is not yet profitable.
The more interesting move is geographic. Chinese humanoid makers hold a supply chain and cost advantage that their electric-car counterparts did not have at the same age, which means exports can become a growth engine earlier. Humanoid exports from China rose 210 per cent year on year in the first quarter, and Bloomberg argued on 14 October that the country could lead a market worth USD 5 trillion.
Agibot partner and co-president Jiang Qingsong says the company targets more than 30 per cent of 2026 sales from overseas, with a path above 50 per cent. Morgan Stanley compares the sector to electric vehicles in 2018 to 2020 and expects a hundredfold increase in global shipments over five years, with Chinese manufacturers holding the chain.
The walls are real. Market access depends on compliance capability, and Tesla has said its third-generation Optimus is ready for volume production. Musk has said Optimus and Cybercab will account for most of Tesla’s value. Hardware reliability, generalisation of physical AI models, cost control, standards and data loops remain the binding constraints.
Editor’s note: This is an adapted translation of the original OFweek report. It has been trimmed and restructured for readability for an international business audience. The full original (in Chinese) is at https://robot.ofweek.com/2026-10/ART-898890-8420-30708767.html.